- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Potenzieller Lizenzdeal für Krebstherapie katapultiert OSR Holdings-Aktie nach oben | 2 | Investing.com Deutsch | ||
| 14.11. | OSR Holdings names Vaximm co-founder as CEO of subsidiary | 5 | Investing.com | ||
| 14.11. | OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion | 104 | PR Newswire | BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm... ► Artikel lesen | |
| 12.11. | OSR Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10. | "You'll get nothing": OSR CEO's message sparks employee revolt amid collapse | 7 | CTech | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 20.10. | Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target | 290 | Newsfile | New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month... ► Artikel lesen | |
| 16.10. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | OSR Holdings announces definitive agreement to acquire Woori IO | 6 | Seeking Alpha | ||
| 14.10. | OSR Holdings übernimmt südkoreanischen Spezialisten für nicht-invasive Blutzuckermessung | 2 | Investing.com Deutsch | ||
| 14.10. | OSR Holdings to acquire noninvasive glucose monitoring firm Woori IO | 1 | Investing.com | ||
| 14.10. | OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care | 86 | PR Newswire | BELLEVUE, Wash., Oct. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO... ► Artikel lesen | |
| 23.09. | OSR Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.09. | OSR Holdings verstößt gegen NASDAQ-Mindestkursanforderung | - | Investing.com Deutsch | ||
| 09.09. | OSR Holdings receives Nasdaq notice for minimum bid price non-compliance | 1 | Seeking Alpha | ||
| 09.09. | OSR Holdings receives Nasdaq minimum bid price deficiency notice | 2 | Investing.com | ||
| 09.09. | OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity | 104 | PR Newswire | BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (Nasdaq: OSRH) today announced that on September 5, 2025, it received a written notification from... ► Artikel lesen | |
| 09.09. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.08. | OSR Holdings ändert Vereinbarungen mit White Lion Capital und beruft Hauptversammlung ein | 2 | Investing.com Deutsch | ||
| 20.08. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,900 | -1,66 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| CARISMA THERAPEUTICS INC | 0,038 | +14,85 % | XFRA W2J: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,404 | +0,89 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| CORMEDIX | 8,100 | -3,57 % | H.C. Wainwright Raises the PT on CorMedix Inc. (CRMD), Keeps a Buy | ||
| MINERVA NEUROSCIENCES | 3,660 | 0,00 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| REPLIMUNE | 8,000 | 0,00 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,164 | -9,39 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.07.2025 | Das Instrument C4X FR0010095596 VALERIO TH AC.PORT.EO-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 24.07.2025 The instrument C4X FR0010095596 VALERIO TH AC.PORT.EO-,01 EQUITY is traded ex capital... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,640 | +6,15 % | Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed private placement led by Samsara BioCapital... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 13,370 | -5,71 % | This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| IO BIOTECH | 0,789 | +6,84 % | IO Biotech meldet Rücktritt des Chief Accounting Officer und Neubesetzung der Position | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | ||
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,145 (+31,27 %) liegt der Kurs bei 0,608 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.